Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases that have high unmet medical needs. Its flagship product, LUPKYNIS (voclosporin), serves as the first FDA-approved oral therapy for adult patients with active lupus nephritis, a serious kidney complication of lupus. The company also advances aritinercept, a dual inhibitor targeting B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), designed for potential use in various autoimmune conditions. Aurinia Pharmaceuticals Inc. engages in research, development, and commercialization within the biotechnology sector of healthcare, emphasizing innovative treatments to address gaps in patient care. It maintains collaborations, such as with Otsuka Pharmaceutical Co., Ltd., to support its therapeutic pipeline. Founded in 1993 and headquartered in Edmonton, Canada, Aurinia Pharmaceuticals Inc. plays a vital role in advancing oral and biologic therapies for autoimmune disorders, contributing to improved outcomes in rheumatology and nephrology.